Prolia is a medicine used to treat the following conditions: - osteoporosis (a disease that makes bones fragile) in women who have been through the menopause and in men who have an increased risk of fracture (broken bones). In women who have been through the menopause Prolia reduces the risk of fractures in the spine and elsewhere in the body, including in the hip; - bone loss in men receiving treatment for prostate cancer that increases their risk of Prolia reduces the risk of fractures in the spine; - bone loss in adults at increased risk of fractures who are treated long term with corticosteroid medicines given by mouth or injection. The medicine contains the active substance denosumab.
Therapeutic Indication
### Therapeutic indication Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women Prolia significantly reduces the risk of vertebral, non vertebral and hip fractures. Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. In men with prostate cancer receiving hormone ablation, Prolia significantly reduces the risk of vertebral fractures.
Therapeutic Area (MeSH)
ATC Code
M05BX04
ATC Item
denosumab
Pharmacotherapeutic Group
Drugs for treatment of bone diseases
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| denosumab | N/A | 地舒单抗 |
EMA Name
Prolia
Medicine Name
Prolia
Aliases
N/A
